Cell line · CVCL_1258
HCC1806
Cancer cell line, Homo sapiens. Breast acantholytic squamous cell carcinoma. 93 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. HCC1806. Cell lines, record CVCL_1258. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1258
On this page
Cell line
As Cellosaurus gives it.
- Name
- HCC1806
- Accession
- CVCL_1258
- RRID
- RRID:CVCL_1258
- Synonyms
- Hcc1806, HCC-1806, Hamon Cancer Center 1806
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 60Y
- Category
- Cancer cell line
- Diseases
- Breast acantholytic squamous cell carcinoma (NCIt C40359)
- Derived from
- Breast (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers93
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| VCP-Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cytotoxic Dihydroagarofuran Sesquiterpenoids Isolated From the Roots of Tripterygium wilfordii. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycolytic enolase 1-induced H4K12 lactylation activates quiescent breast cancer stem-like cells in triple-negative breast cancer. | Signal Transduct Target Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E modulates vulnerability to CDC7 kinase inhibition. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates. | Antib Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 93
See all 93 papersRelatives10
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HCC1806-EGFP | CVCL_C8VV | Cell lines | |
| Derived from it | HCC1806r5-F1500 | CVCL_D6VJ | Cell lines | |
| Derived from it | HCC1806rCDDP500 | CVCL_D6VE | Cell lines | |
| Derived from it | HCC1806rDOX12.5 | CVCL_D6VF | Cell lines | |
| Derived from it | HCC1806rERI50 | CVCL_D6VG | Cell lines | |
| Derived from it | HCC1806rGEM20 | CVCL_D6VH | Cell lines | |
| Derived from it | HCC1806rPCL20 | CVCL_D6VI | Cell lines | |
| Derived from it | HCC1806rYM155_20nM | CVCL_RS40 | Cell lines | |
| Derived from it | HyCyte HCC1806-Luc | CVCL_E3H9 | Cell lines | |
| Derived from it | Ubigene HCC1806 ADPRS KO | CVCL_D8GW | Cell lines |
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-2335 | ATCC | |
| CLS | 300467 | CLS | |
| KCB | KCB 2014032YJ | Cellosaurus | |
| Ubigene | YC-C073 | Ubigene |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1258
GET https://conductscience.org/api/cell-lines/v1/CVCL_1258/papers?page=2